Trial results for the SMMART-ACT study (NCT06630325) investigating osimertinib and other interventions for advanced sarcoma, prostate, breast, ovarian, or pancreatic cancers were posted on ClinicalTrials.gov on 2026-04-28. This Phase 2 trial was terminated with an enrollment of 6 participants.
Background
The SMMART-ACT trial aimed to test a precision medicine approach (serial measurements of molecular and architectural response to therapy [SMMART])-adaptive clinical treatment [ACT] in patients with advanced cancers. This approach uses genetic and protein tests to understand cancer changes and potential drug efficacy.
Trial design
The SMMART-ACT study (NCT06630325) was a Phase 2 trial that enrolled 6 participants. The study investigated a precision medicine approach for patients diagnosed with advanced breast carcinoma, advanced malignant solid neoplasm, advanced ovarian carcinoma, advanced pancreatic carcinoma, or advanced prostate carcinoma. Interventions included abemaciclib, exemestane, gemcitabine, letrozole, and osimertinib.
What this means
The termination of the SMMART-ACT trial with limited enrollment means that no efficacy or safety data from this specific study are available for the investigated precision medicine approach using osimertinib and other agents in advanced cancers. The trial's early termination indicates that it did not progress to generate definitive results regarding the SMMART-ACT strategy.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT06630325, titled "A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer," were posted on 2026-04-28 on clinicaltrials.gov.